6 Recommendations for further research

6.1 The Committee noted that a large trial is planned that will compare low-dose temozolomide with dose-intense temozolomide, and that this trial is expected to include stratification of patients by MGMT promoter methylation status.

6.2 The Committee noted that there was an ongoing trial comparing PCV therapy with temozolomide in the treatment of recurrent high‑grade glioma.

6.3 The Committee recommended that specialist centres should establish audit criteria to confirm that maximal resection of 90% or more has been achieved using comparisons of preoperative and postoperative MRI.